Whole genome sequencing reveals novel resistance-conferring mutations and large genome deletions in drug-resistant Mycobacterium tuberculosis isolates from Indonesia.
Journal of global antimicrobial resistance·
- DOI
- 10.1016/j.jgar.2025.07.017
- PMID
- 40706998
- PMCID
- —
- OpenAlex
- W4412558991
- Study type
- Genomic study
- Publisher
- Publisher unavailable
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The findings indicate that some resistance-associated mutations or deletions identified in this sample may not be detected by routine diagnostic methods described by the authors. The abstract also states that known resistance mutations could be assessed using Xpert MTB/XDR together with Xpert MTB/RIF, while rapid methods for detecting resistance to newer drugs remain needed.
Structured evidence summary
Research question
The study assessed drug-resistance profiles of Mycobacterium tuberculosis isolates from West Java, Indonesia using phenotypic drug-susceptibility testing and whole-genome sequencing.
Study design
This was a genomic study combining phenotypic drug-susceptibility testing with whole-genome sequencing. The analysis included 142 rifampicin-resistant isolates identified using the Xpert MTB/RIF platform.
Population and setting
The study examined 142 Mycobacterium tuberculosis isolates from West Java, Indonesia, all identified as rifampicin-resistant by Xpert MTB/RIF.
Main findings
Among the 142 isolates, 107 (75%) showed combined high-level isoniazid and rifampicin resistance. Within those 107 isolates, two had previously unreported katG mutations and three had large deletions involving katG. No pre-existing resistance mutations to bedaquiline, pretomanid, or linezolid were detected in the study sample.
Public-health relevance
The findings indicate that some resistance-associated mutations or deletions identified in this sample may not be detected by routine diagnostic methods described by the authors. The abstract also states that known resistance mutations could be assessed using Xpert MTB/XDR together with Xpert MTB/RIF, while rapid methods for detecting resistance to newer drugs remain needed.
Important limitations
The supplied evidence does not provide explicit study limitations or enough methodological detail to assess representativeness, sampling procedures, or the broader applicability of the findings. This summary is therefore limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
This article is relevant for discovering evidence about tuberculosis drug resistance, genomic findings, and diagnostic considerations in Indonesia. It provides context from a single study sample and should not be interpreted as confirmation of a current surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 9 auditable classifier relationships to diseases, places, topics, and study design.